跳至主要内容
临床试验/NCT00825578
NCT00825578已完成3 期

Comparative Study of Bronchoscopic Lung Volume Reduction to Evaluate Relative Efficacy in Patients With Non-Upper Lobe Emphysema

Royal Brompton & Harefield NHS Foundation Trust1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2009年1月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
32
试验地点
1
主要终点
To estimate the difference between study arms in volume changes of the treated lobe(s) by CT scan

研究概览

简要总结

Hypothesis: Patients with advanced emphysema with predominance of the disease in areas other than the upper lobes, as determined by high resolution computed tomography (HRCT), could have a positive response to valve treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18-80 years
  • •Ex-smoker with smoking cessation confirmed by exhaled carbon monoxide (CO) levels
  • •Moderate to severe airflow obstruction FEV1 <50% Predicted
  • •Severe dyspnoea - mMRC ≥2
  • •Hyperinflation - total lung capacity (TLC) ≥100% predicted, RV ≥150% predicted
  • •Optimum COPD treatment for at least 6 weeks
  • •No COPD exacerbation for at least 6 weeks
  • •Less than 4 admissions for exacerbation in the preceding 12 months

排除标准

  • •Patient unable to provide informed consent
  • •Patient without clear targets for airflow re-distribution
  • •Total lung CO uptake (TLCO) <15% predicted and FEV1 <15% predicted
  • •pO2 on air <6.0kPa
  • •pCO2 on air >8.0kPa
  • •Neurological, rheumatological or other cause of exercise limitation
  • •Other major medical illness, e.g. lung cancer that will limit participation
  • •Production of purulent sputum more often than not (more than 50% of days)
  • •Clinically significant bronchiectasis
  • •Large bulla - more than 1/3 of hemithorax volume (i.e. where bullectomy would be more suitable) on CT scan
  • •Arrhythmia or cardiovascular disease that poses a risk during procedure or exercise
  • •Prednisolone dose greater than 15mg a day
  • •Significant pulmonary hypertension - RVSP ≥45mmHg
  • •Left ventricular failure - left ventricular ejection fraction <45% or left ventricular fraction shortening <23%
  • •Prior LVRS or lobectomy
  • •Lung nodule requiring surgery
  • •Subject completed or is participating in a standard pulmonary rehabilitation program within 3 months of enrolment
  • •Female of childbearing age with positive pregnancy test
  • •Subject participated in a research study of investigational drug or device in prior 30 days
  • •Subject taking clopidogrel, warfarin, or other anticoagulants and unable to abstain for 5 days pre-procedure

研究组 & 干预措施

1

Active Comparator

Upper-lobe predominant emphysema

干预措施: Intra-bronchial valve (Spiration IBV) (Device)

2

Active Comparator

Non-upper lobe predominant emphysema

干预措施: Intra-bronchial valve (Spiration IBV) (Device)

结局指标

主要结局

To estimate the difference between study arms in volume changes of the treated lobe(s) by CT scan

时间窗: 6 months

次要结局

  • To estimate the difference between study arms in volume changes of the non-treated lobes by CT scan(6 months)
  • To estimate the difference between study arms in residual volume(6 months)
  • To estimate the difference between study arms in FEV1(6 months)
  • To estimate the difference between study arms in gas transfer(6 months)
  • To estimate the difference between study arms in modified MRC dyspnoea score(6 months)
  • To estimate the difference between study arms on a 6 minute walk test(6 months)
  • To estimate the difference between study arms in disease specific health status(6 months)
  • To estimate the difference between study arms in dynamic hyperinflation during cycle ergometry(6 months)
  • To estimate the difference between study arms in changes in respiratory and quadriceps muscle strength(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验